Pfizer, Novartis ink respiratory deal

Share this article:

Pfizer has inked a deal to market Novartis's chronic obstructive pulmonary disease drug Seebri Breezhaler (glycopyrronium bromide) and the Ultimo Breezhaler (indacaterol/glycopyrronium bromide) in Great Britain. Pfizer said in a statement that the country's National Health Service estimates around three million residents have COPD, one of the most common respiratory diseases.

The category has gotten a significant amount of attention of late, such as GlaxoSmithKline's efforts to shore up its Ellipta franchise and AstraZeneca's recent Almirall purchase to beef up its respiratory portfolio.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.